China-based Walvax Biotechnology Co., Ltd (SHE: 300142) has achieved a significant milestone with its bivalent human papillomavirus vaccine, which has received pre-qualification (PQ) status from the World Health Organization (WHO). This vaccine, designed to prevent cervical cancer and other diseases associated with high-risk HPV types 16 and 18, was commercially launched in mainland China in May 2022 following regulatory approval in March of the same year.
The PQ status from WHO signifies that Walvax Bio’s vaccine is now eligible for procurement by UNICEF and other United Nations agencies, potentially expanding its reach to global markets and contributing to the global effort to combat HPV-related diseases.- Flcube.com
